Literature DB >> 14743356

Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.

Connie Marras1, Anthony Lang, Murray Krahn, George Tomlinson, Gary Naglie.   

Abstract

The impact of dyskinesias and motor fluctuations on quality of life (QOL) at various stages in the course of Parkinson's disease (PD) is not well understood. In 301 subjects with early PD enrolled in a clinical trial (CALM-PD), we quantified the impact of motor complications on QOL and investigated how this changes over time. We also compared QOL related to demographic and treatment characteristics. The presence of dyskinesias was associated with visual analogue scale (VAS) scores 3.0 of 100 points higher (better) than those without dyskinesias in years 1 to 2, even when adjusting for Unified Parkinson's Disease Rating Scale (UPDRS) motor scores. The positive association between dyskinesias and QOL scores was more marked in older patients. In years 3 to 4, dyskinesias no longer had a significant relationship with QOL. Younger subjects had higher VAS scores. Gender, motor fluctuations, and treatment regimen had no significant association with QOL, although a trend was found toward a small negative effect of motor fluctuations on QOL. We conclude that motor complications that occur within the first 4 years of treatment of PD do not have a significant negative effect on quality of life as measured by a visual analogue scale for most patients. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14743356     DOI: 10.1002/mds.10642

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  21 in total

1.  Pharmacotherapy in Parkinson's disease: case studies.

Authors:  Tiago Mestre; Joaquim J Ferreira
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

2.  Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.

Authors:  Cicely Kerr; Emily J Lloyd; Charlotte E Kosmas; Helen T Smith; James A Cooper; Karissa Johnston; Emma McIntosh; Andrew J Lloyd
Journal:  Qual Life Res       Date:  2015-12-01       Impact factor: 4.147

3.  Scales in Parkinson's disease.

Authors:  Georg Ebersbach; Horst Baas; Ilona Csoti; Martina Müngersdorf; Günther Deuschl
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

4.  Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.

Authors:  Katia Noyes; Andrew W Dick; Robert G Holloway
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 5.  The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases.

Authors:  Jenny Lam; Nichole Coleman; April Lourdes A Garing; Heike Wulff
Journal:  Expert Opin Ther Targets       Date:  2013-07-25       Impact factor: 6.902

Review 6.  Early versus delayed initiation of pharmacotherapy in Parkinson's disease.

Authors:  Matthias Löhle; Carl-Johan Ramberg; Heinz Reichmann; Anthony H V Schapira
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

Review 7.  An update on the diagnosis and treatment of Parkinson disease.

Authors:  Philippe Rizek; Niraj Kumar; Mandar S Jog
Journal:  CMAJ       Date:  2016-05-24       Impact factor: 8.262

8.  Patient and caregiver perceptions of the social impact of advanced Parkinson's disease and dyskinesias.

Authors:  Alexander Khlebtovsky; Amihai Rigbi; Eldad Melamed; Ilan Ziv; Israel Steiner; Alona Gad; Ruth Djaldetti
Journal:  J Neural Transm (Vienna)       Date:  2012-03-22       Impact factor: 3.575

9.  A comprehensive model of health-related quality of life in Parkinson's disease.

Authors:  M Visser; S M van Rooden; D Verbaan; J Marinus; A M Stiggelbout; J J van Hilten
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

Review 10.  Levodopa-induced dyskinesias and their management.

Authors:  Francesca Del Sorbo; Alberto Albanese
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.